Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Li Zhou, Sha Tan, Yi-long Shan, Yu-ge Wang, Wei Cai, Xue-hong Huang, Xi-yuan Liao, Hai-yan Li, Lei Zhang, Bing-jun Zhang & Zheng-qi Lu. (2016) Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats. Neuropsychiatric Disease and Treatment 12, pages 3145-3152.
Read now
Read now
Articles from other publishers (20)
Dhivya Bakthavachalam & Sivakumar Arumugam. (2023) Identification and characterization of bioactive peptides from marine crustacean crabs: a possible drug candidate for Alzheimer’s disease. Aquaculture International.
Crossref
Crossref
Xiang Yu, Yan Zhang, Minjie Zhang, Yafang Chen & Wude Yang. (2022) Natural products as sources of acetylcholinesterase inhibitors: Synthesis, biological activities, and molecular docking studies of osthole-based ester derivatives. Frontiers in Plant Science 13.
Crossref
Crossref
Yolanda TejaDwi Rachma HelianthiIrma Nareswari. (2021) The Role of Medical Acupuncture Therapy in Alzheimer's Disease. Medical Acupuncture 33:6, pages 396-402.
Crossref
Crossref
Vivitri Prasasty, Muhammad Radifar & Enade Istyastono. (2018) Natural Peptides in Drug Discovery Targeting Acetylcholinesterase. Molecules 23:9, pages 2344.
Crossref
Crossref
Yujie Jia, Xuezhu Zhang, Jianchun Yu, Jingxian Han, Tao Yu, Jiangwei Shi, Lan Zhao & Kun Nie. (2017) Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial. BMC Complementary and Alternative Medicine 17:1.
Crossref
Crossref
Derek K. Smith, Miao He, Chun-Li Zhang & Jialin C. Zheng. (2017) The therapeutic potential of cell identity reprogramming for the treatment of aging-related neurodegenerative disorders. Progress in Neurobiology 157, pages 212-229.
Crossref
Crossref
Kang Joon Lee, Seong-Jin Cho, Byeong Chae Kim, Minseok Park & Jae-Hong Lee. (2016) Caregiver Preference and Treatment Compliance in Patients with Mild-to-Moderate Alzheimer’s Disease in South Korea: RECAP Study Results. Advances in Therapy 34:2, pages 481-494.
Crossref
Crossref
Jin-Sun Lee, Seul-Ki Park & Sang-Kyu Park. (2016) Electrolyzed-reduced water mitigates amyloid beta toxicity via DAF-16 in C. elegans. Toxicology and Environmental Health Sciences 8:1, pages 56-61.
Crossref
Crossref
Taizong Wu, Cheng Jiang, Ling Wang, Susan L. Morris-Natschke, Hui Miao, Lianquan Gu, Jun Xu, Kuo-Hsiung Lee & Qiong Gu. (2015)
3,5-Diarylpyrazole Derivatives Obtained by Ammonolysis of the Total Flavonoids from
Chrysanthemum indicum
Extract Show Potential for the Treatment of Alzheimer’s Disease
. Journal of Natural Products 78:7, pages 1593-1599.
Crossref
Crossref
Eugene O'Hare, David I.C. Scopes, Eun-Mee Kim, Philip Palmer, David Spanswick, Bridgeen McMahon, Hozefa Amijee, Edmund Nerou, J. Mark Treherne & Ross Jeggo. (2013) Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease. The International Journal of Neuropsychopharmacology 17:01, pages 117-126.
Crossref
Crossref
Eugene O'Hare, David I.C. Scopes, Eun-Mee Kim, Philip Palmer, Martyn Jones, Andrew D. Whyment, David Spanswick, Hozefa Amijee, Edmund Nerou, Bridgeen McMahon, J. Mark Treherne & Ross Jeggo. (2013) Orally bioavailable small molecule drug protects memory in Alzheimer's disease models. Neurobiology of Aging 34:4, pages 1116-1125.
Crossref
Crossref
James E Galvin. (2012) Optimizing diagnosis and management in mild-to-moderate Alzheimer’s disease. Neurodegenerative Disease Management 2:3, pages 291-304.
Crossref
Crossref
Joao P. Lopes & Paula Agostinho. (2011) Cdk5: Multitasking between physiological and pathological conditions. Progress in Neurobiology 94:1, pages 49-63.
Crossref
Crossref
Roongpetch Keowkase, Marwa Aboukhatwa & Yuan Luo. (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59:4-5, pages 358-365.
Crossref
Crossref
Ruth Remington, Amy Chan, Alicia Lepore, Elizabeth Kotlya & Thomas B. Shea. (2010) Apple Juice Improved Behavioral But Not Cognitive Symptoms in Moderate-to-Late Stage Alzheimer’s Disease in an Open-Label Pilot Study. American Journal of Alzheimer's Disease & Other Dementiasr 25:4, pages 367-371.
Crossref
Crossref
Amy Chan, James Paskavitz, Ruth Remington, Shelly Rasmussen & Thomas B. Shea. (2008) Efficacy of a Vitamin/Nutriceutical Formulation for Early-stage Alzheimer's Disease: A 1-year, Open-label Pilot Study With an 16-Month Caregiver Extension. American Journal of Alzheimer's Disease & Other Dementiasr 23:6, pages 571-585.
Crossref
Crossref
Puneet Kumar & Anil Kumar. (2009) Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: Possible behavioural, biochemical and cellular alterations. European Journal of Pharmacology 615:1-3, pages 91-101.
Crossref
Crossref
Ruth Remington, Amy Chan, James Paskavitz & Thomas B. Shea. (2008) Efficacy of a Vitamin/Nutriceutical Formulation for Moderate-stage to Later-stage Alzheimer's disease: A Placebo-controlled Pilot Study. American Journal of Alzheimer's Disease & Other Dementiasr 24:1, pages 27-33.
Crossref
Crossref
M. G. Kaplitt. 2009. Textbook of Stereotactic and Functional Neurosurgery. Textbook of Stereotactic and Functional Neurosurgery
3061
3082
.
Demetrios Vakratsas & Ceren Kolsarici. (2008) A dual-market diffusion model for a new prescription pharmaceutical. International Journal of Research in Marketing 25:4, pages 282-293.
Crossref
Crossref